SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Durkin Brian L (Last) (First) (Middle) 1 NORTH WAUKEGAN ROAD (Street) NORTH CHICAGO IL 60064 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/16/2018	3. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ ABBV ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) VP, Controller	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, $0.01 par value	4,251	D
Common stock, $0.01 par value	253	I	By spouse(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(2)	(2)	07/24/2026	Common stock	5,240	64.12	D
Option (right to buy)(3)	(3)	02/15/2027	Common stock	7,180	61.36	D
Option (right to buy)(4)	02/15/2019	02/14/2028	Common stock	3,110	114.36	D

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of all securities held by his spouse.

2. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 1,747 shares on 7/25/2017 and as to 1,746 shares on 7/25/2018, and becomes exercisable as to 1,747 shares on 7/25/2019.

3. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,394 shares on 2/16/2018, and becomes exercisable as to 2,393 shares on 2/16/2019 and as to 2,393 shares on 2/16/2020.

4. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 1,037 shares on 02/15/2019, 1,036 shares on 02/15/2020, and 1,037 shares on 02/15/2021.

	Steven Scrogham, attorney-in-fact for Brian L. Durkin	10/24/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY


	The undersigned constitutes and appoints LAURA J. SCHUMACHER,
KATHLEEN M.S. SCHEIDT, JENNIFER M. LAGUNAS and STEVEN L. SCROGHAM,
and each of them individually, as the undersigned's true and lawful
attorney-in-fact and agent, with full power  of substitution and
re-substitution, for the undersigned and in the  undersigned's name,
place and stead, to prepare and sign any and all Securities and
Exchange Commission  ("SEC") Notices of Proposed Sales of Securities
pursuant to Rule 144 under the Securities  Act of 1933 on Form 144,
all SEC statements on Forms 3, 4 and 5 as required under Section 16(a)
of the Securities Exchange Act of 1934, including a Form ID and any
other  documents necessary to obtain codes and passwords necessary
to make electronic filings,  and any amendments or successors to such
forms, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, granting unto said
attorney-in-fact and agent full power and authority to do and perform
each act and thing requisite, necessary or desirable to be done under
said Rule 144 and Section 16(a), as fully for all intents and purposes
as the undersigned might or could do in person, hereby ratifying and
confirming all that said attorney-in-fact and agent may lawfully do or
cause to be done by virtue hereof.

	A copy of this power of attorney shall be filed with the SEC.
The authorization set forth above shall continue in full force and
effect until the undersigned is no longer required to file Forms 144,
3, 4, or 5 or if earlier, until the undersigned revokes such
authorization by written instructions to the attorney-in-fact.


Date:  October 17, 2018

/s/ Brian L. Durkin
Signature of Reporting Person

Brian L. Durkin
Name


AbbVie Inc.
1 N. Waukegan Road
North Chicago, IL 60064